There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LAG-3


Here comes a serial of ready-to-use universal ELISA kits to simplify your drug R&D. Request for free sample.

LAG-3 Molecule Information

Name:Lymphocyte activation gene 3 protein
Target Synonym:LAG-3;CD223;FDC;LAG3;Protein FDC
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:17
Lastest Research Phase:Phase ?

LAG-3 Protein Product ListCompare or Buy

LAG-3 Part of Bioactivity data

LA3-H82F3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that Biotinylated Human LAG-3, Mouse IgG2a Fc,Avitag (Cat. No. LA3-H82F3) can bind to daudi cell surface. The concentration of LAG-3 used is 0.3 μg/mL (Routinely tested).

LA3-H52Aa-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that Human LAG3, Mouse IgG2a Fc Tag (Cat. No. LA3-H52Aa) can bind to daudi cell surface. The concentration of LAG3 used is 0.3 μg/mL (Routinely tested).


Anti-LAG-3 MAb (Human IgG1) captured on CM5 chip via Anti-Human IgG Fc antibodies surface, can bind Human LAG-3, His Tag (Cat. No. LA3-H5222) with an affinity constant of 4.57 nM as determined in a SPR assay (Biacore T200) (Routinely tested).


Loaded Anti-LAG-3 MAb (Human IgG1) on AHC Biosensor, can bind Human LAG-3, His Tag (Cat. No. LA3-H5222) with an affinity constant of 7.47 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

LAG-3 Customer Reviews

LAG-3 Molecule Synonym Name


LAG-3 Molecule Background

Lymphocyte activation gene 3 protein (LAG3) is also known as CD antigen CD223 and protein FDC, which belongs to immunoglobulin (Ig) superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. LAG3 /CD223 involved in lymphocyte activation. LAG3 /CD223 binds to HLA class-II antigens.

LAG-3 References

LAG-3 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Fianlimab REGN-3767 Phase Ⅰ Regeneron Pharmaceutical, Sanofi Malignancies Details
Nivolumab/Relatlimab BMS-936558/BMS-986016; BMS-986213 Phase Ⅲ Bristol-Myers Squibb Melanoma Details
Chlorogenic acid Phase Ⅲ Sichuan Jiuzhang Biotech Glioblastoma Details
SHR-1802 SHR-1802 Phase Ⅰ Shanghai Hengrui, Jiangsu Hengrui Medicine, Suzhou Shengdiya Cancer Details
TSR-033 TSR-033,TSR 033,TSR033,GSK-4074386 Phase Ⅱ AnaptysBio, Tesaro, GlaxoSmithKline Solid tumours Details
BI-754111 BI-754111 Phase Ⅱ Boehringer Ingelheim Non small cell lung cancer (NSCLC), Solid tumours, Head and neck cancer Details
Ieramilimab LAG-525; IMP-701 Phase Ⅱ Immutep, Novartis, CoStim Triple negative breast cancer, Neuroendocrine tumors (NET), Small cell lung cancer (SCLC), Gastric adenocarcinoma, Diffuse large B cell lymphoma, Esophageal adenocarcinoma, Castration-resistant prostate cancer (CRPC), Solid tumours, Soft tissue sarcoma, Ovarian cancer, Hematological cancer, Melanoma Details
IMP-761 IMP-761 Preclinical Immutep Autoimmune diseases Details
IBI-110 IBI-110 Phase Ⅰ Innovent Biologics Solid tumours, Hematological cancer Details
XmAb-22841 XmAb-22841 Phase Ⅰ Xencor Cancer Details
FS 118 FS-118 Phase Ⅰ F-star, Merck Serono hematological malignancies, Solid tumours Details
LBL-007 LBL-007,LBL007 Phase Ⅰ Nanjing Leads Biolabs Co Ltd Solid tumours, Lymphoma Details
Relatlimab BMS-986016; ONO-4482 Phase Ⅲ Bristol-Myers Squibb, Ono Pharmaceutical Melanoma Details
Sym-022 Sym-022 Phase Ⅰ Symphogen Solid tumours, Lymphoma Details
MGD-013 MGD-013; PD-1 X LAG-3 Phase Ⅲ MacroGenics, Zai Lab Gastric cancer, oesophageal cancer Details
RO-7247669 RO-7247669 Phase Ⅰ Roche Solid tumours Details
GSK-2831781 GSK-2831781; GSK‘-781; ImmuTune-IMP731; IMP-731 Phase Ⅱ Prima BioMed, GlaxoSmithKline Ulcerative colitis Details
INCAGN-2385 INCAGN-02385; INCAGN-2385 Phase Ⅱ Agenus Melanoma Details

This web search service is supported by Google Inc.